Psychiatric Multi-omics and Neuroimaging Project

NCT06580860 | Recruiting

• 1 other identifier: NSFC82201664
• Study Type: observational
• Target: 1,899
• Locations: 1 country
• Sites: 1

Brief Summary

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Conditions

Mental Disorders; Healthy Control

Keywords

schizophrenia; major depressive disorder; autism spectrum disorder; bipolar disorder; magnetic resonance imaging; multi-omics

Outcome Measures

Primary Outcomes (3)

• cortical morphology

  Data were obtained using magnetic resonance scans

  40 minutes

• target gene charaacteristics

  10ml peripheral blood was extracted for gene analysis

  1 day

• scale scores

  The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.

  90 minutes.

Study Arms (6)

PMNP-Healthy Norms

Healthy Norms

Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

PMNP-Subclinical high-risk

Subclinical high-risk

Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

PMNP-Schizophrenia and Psychosis

Schizophrenia and Psychosis patient

Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

PMNP-MDD

major depressive disorder patient

Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

PMNP-ASD

autism spectrum disorder patient

Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

PMNP-BD

bipolar disorder patient

Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

Interventions

Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids DRUG

Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

PMNP-ASD; PMNP-BD; PMNP-Healthy Norms; PMNP-MDD; PMNP-Schizophrenia and Psychosis; PMNP-Subclinical high-risk

Eligibility Criteria

• Age: 13 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment

You may qualify if:

• Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
• Course of disease: \<24 months
• Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks
• No nuclear magnetic contraindications.

You may not qualify if:

• Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
• Have a major physical disease or infectious disease
• History of coma and serious neurological disease 4.MRI contraindications.

Sponsors & Collaborators

• mingjun Zhong: lead

Study Sites (1)

The Second Xiangya hospital of central south univerity

Changsha, Hunan, 410000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

10ml peripheral blood

MeSH Terms

Conditions

Mental Disorders; Schizophrenia; Depressive Disorder, Major; Autism Spectrum Disorder; Bipolar Disorder

Interventions

Antipsychotic Agents; Antidepressive Agents

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Depressive Disorder; Mood Disorders; Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Bipolar and Related Disorders

Intervention Hierarchy (Ancestors)

Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses; Central Nervous System Agents; Therapeutic Uses; Psychotropic Drugs

Central Study Contacts

Yunzhi Pan

CONTACT

15074818197; panyunzhi@csu.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 28, 2024
• First Posted: August 30, 2024
• Study Start: January 1, 2016
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027
• Last Updated: March 13, 2026

Record last verified: 2026-03

Locations

CN (1)